Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock
July 27, 2023 23:20 ET
|
Inozyme Pharma Inc.
BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...
Inozyme Pharma, Inc. Announces Proposed Offering of Common Stock
July 27, 2023 16:33 ET
|
Inozyme Pharma Inc.
BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...
Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency
July 26, 2023 07:30 ET
|
Inozyme Pharma Inc.
- Change in plasma pyrophosphate (PPi) as primary endpoint in the U.S. and co-primary endpoint in the EU for planned ENERGY-3 pivotal trial in pediatric patients - - ENERGY-3 pivotal trial in...
Inozyme Pharma to Provide ENPP1 Deficiency Program Update on July 26, 2023
July 19, 2023 08:30 ET
|
Inozyme Pharma Inc.
– Conference call and webcast to be held on July 26, 2023, at 8am ET – BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage...
Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701
June 27, 2023 08:30 ET
|
Inozyme Pharma Inc.
BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...
Inozyme Pharma to Present at the Jefferies Healthcare Conference
June 02, 2023 07:30 ET
|
Inozyme Pharma Inc.
BOSTON, June 02, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...
Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights
May 09, 2023 08:30 ET
|
Inozyme Pharma Inc.
- Upcoming clinical and regulatory milestones remain on track with previous guidance – - Current cash, cash equivalents and short-term investments anticipated to fund cash flow requirements into...
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2023 08:30 ET
|
Inozyme Pharma Inc.
BOSTON, May 03, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...
Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)
April 14, 2023 08:30 ET
|
Inozyme Pharma Inc.
BOSTON, April 14, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...
Inozyme Pharma to Participate at the 22nd Annual Needham Virtual Healthcare Conference
April 11, 2023 08:30 ET
|
Inozyme Pharma Inc.
BOSTON, April 11, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical- stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...